Silverfleet Capital

Aesica Pharmaceuticals

Business overview

Aesica Pharmaceuticals is one of the world’s top 12 pharmaceutical contract manufacturers (“CMOs”). With manufacturing and development facilities in the UK, Germany and Italy, Aesica is forecast to turnover in excess of €180 million for 2011.

Aesica has the expertise to both develop and manufacture primary (API) and secondary stage (finished product dosage form) pharmaceuticals, partnering with pharmaceutical companies throughout the key stages of a drug’s life cycle to supply product from initial development through to final commercial supply.

Aesica was founded in 2004 when the management team acquired a BASF production facility in Cramlington, Northumberland, and today supplies many of the world’s leading pharmaceutical companies. The company’s unique proposition lies in its flexible and bespoke approach to service delivery, as well as a capability to supply to each stage of pharmaceutical development. The long-established and proven expertise within Aesica enables it to provide primary and secondary contract manufacturing services to the highest possible regulatory standards.

Investment rationale

Global outsourcing of pharmaceutical manufacturing was worth approximately $44 billion in 2010, and is forecast to grow at c7% for the foreseeable future. This growth will principally be directed towards those CMOs that are focussed on quality, reliability, delivery and excellent customer service. Aesica’s reputation within the marketplace as such a high quality CMO partner, with the scale and breadth of service capability to serve a range of outsourcing opportunities, makes it well positioned to win new contracts and to acquire further sites.